Blog Archives - Page 10 of 51

Older adults willing to reduce number of medications, study finds

Are patients’ attitudes the biggest barrier to deprescribing?

Why are American voters so concerned about health care? Because the high cost of health care is causing devastating financial harm.

Should we blame researchers who evaluate cost-effectiveness of drugs for restricting access to pricey new meds?

If you thought the only takeaway from ORBITA was “stents don’t work,” you’re missing the point, says Dr. Vikas Saini in Health Affairs.

What the response to the ORBITA trial reveals about inertia in clinical practice, from Shannon Brownlee.

Is there a tradeoff between underdiagnosis and overdiagnosis, or do they stem from the same problems?

What is the difference between collaboration and conflicts of interest?

Why reporters need to look more carefully at evidence for costly treatments…

Are omega-3 supplements the “new paradigm” in cardiovascular treatment? Not yet…

Persistent stereotypes and lack of access to clinical trials contribute to worse outcomes for black cancer patients.